These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8213502)

  • 1. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications.
    Goldman L; Goldman PA; Williams LW; Weinstein MC
    Am J Cardiol; 1993 Sep; 72(10):75D-79D. PubMed ID: 8213502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
    Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
    Goldman L; Weinstein MC; Goldman PA; Williams LW
    JAMA; 1991 Mar; 265(9):1145-51. PubMed ID: 1899896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
    Perreault S; Hamilton VH; Lavoie F; Grover S
    Arch Intern Med; 1998 Feb; 158(4):375-81. PubMed ID: 9487235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction.
    Elliott WJ; Weir DR
    Am J Health Syst Pharm; 1999 Sep; 56(17):1726-32. PubMed ID: 10512503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain.
    Plans-Rubió P
    Pharmacoeconomics; 1998 May; 13(5 Pt 2):623-43. PubMed ID: 17165328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of statins.
    Huse DM; Russell MW; Miller JD; Kraemer DF; D'Agostino RB; Ellison RC; Hartz SC
    Am J Cardiol; 1998 Dec; 82(11):1357-63. PubMed ID: 9856919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of cholesterol-lowering drugs: a review of the evidence.
    Thorvik E; Aursnes I; Kristiansen IS; Waaler HT
    Wien Klin Wochenschr; 1996; 108(8):234-43. PubMed ID: 8686314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
    Illingworth DR; Bacon S
    Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Heterozygous family hypercholesterolemia: study of use of statins under clinical practice conditions].
    Portela Romero M; Pombo Romero J; Bugarín González R; Tasende Souto M
    Aten Primaria; 2006 Oct; 38(6):333-8. PubMed ID: 17173797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A trial of long-term lovastatin treatment in patients with a heterozygous form of hereditary hypercholesterolemia].
    Alidzhanova KhG; Eliseev AO; Tvorogova MG; Buriachkovskaia LI; Chuĭkin NA; Tripol'skaia LV; Kukharchuk VV
    Ter Arkh; 1997; 69(8):13-7. PubMed ID: 9381383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How effective is drug therapy in heterozygous familial hypercholesterolemia?
    Illingworth DR
    Am J Cardiol; 1993 Sep; 72(10):54D-58D. PubMed ID: 8213497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.